The company, GW Pharma, is in the process of creating a collection of cannabinoid-based drugs, including one that takes aim at diabetes. The first of this type of drug the company has produced is Sativex, a nasal spray used to treat spasms associated with multiple sclerosis. Sativex has been okayed in eight countries, and is currently awaiting FDA approval in the United States.

The diabetes drug, GWP4204, is currently in its second phase of testing after a small but successful double-blind study. That study featured 62 type 2 patients who received various levels of the oral-administered drug or a placebo.”

More: http://diabeteshealth.com/read/2013/07/20/7933/cannabis-derived-drug-for-type-2-enters-phase-2–